Suchergebnisse

search

Such-Filter

Tag
aav
Logo.jpeg.png
Fuse Vectors secures $5.2m to advance cell-free gene therapy technology, led by HCVC
25. Februar 2025 09:00 ET | Fuse Vectors
Copenhagen, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Gene therapy's biggest obstacle isn't science - it's manufacturing. While the field races forward with breakthrough treatments, production remains stuck...
1
EHang Partners with JAC Motors and Guoxian Holdings to Build eVTOL Manufacturing Base in Hefei
24. Februar 2025 23:59 ET | EHang Holdings Limited
GUANGZHOU, China, Feb. 25, 2025 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading Urban Air Mobility (“UAM”) technology platform company,...
1
EHang Launches UAM Exhibition (Experience) Center in Shenzhen's Luohu District, Showcasing First Automated Smart eVTOL Vertiport for EH216-S
21. Januar 2025 23:16 ET | EHang Holdings Limited
GUANGZHOU, China, Jan. 21, 2025 (GLOBE NEWSWIRE) -- EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading Urban Air Mobility (“UAM”) technology platform company,...
Coave Therapeutics l
Coave Therapeutics lève €32 millions d'euros en série A pour accélérer le développement de ses médicaments génétiques de nouvelle génération
09. Januar 2025 03:00 ET | Coave Therapeutics
Le tour de table a été mené par Novo Holdings A/S et Bpifrance (dans le cadre de la stratégie d'investissement InnoBio), avec la participation d'investisseurs américains et européens, Invus et UI...
Coave Therapeutics S
Coave Therapeutics Secures €32 Million ($33 Million) in Series A Financing to Advance its Next-Generation Genetic Medicines
09. Januar 2025 03:00 ET | Coave Therapeutics
Financing co-led by Novo Holdings A/S and Bpifrance (as part of the InnoBio investment strategy) and joined by leading US and EU investors Invus and UI Investissement alongside existing...
ViGeneron_Logo_NEW.png
ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901 and DSMB Approval to Advance Dose Escalation in Phase 1b Retinitis Pigmentosa Trial
08. Januar 2025 08:00 ET | ViGeneron GmbH
VG901 is the first-in-class and only clinical-stage therapy designed to deliver the functional CNGA1 gene intravitreally (IVT) to target retinal photoreceptor cells in patients with retinitis...
ViGeneron_Logo_NEW.png
ViGeneron Announces FDA Clearance of IND for Novel mRNA Trans-Splicing Gene Therapy VG801 to Treat Stargardt Disease and Other ABCA4-Linked Retinal Dystrophies
18. Dezember 2024 08:00 ET | ViGeneron GmbH
VG801 is the first FDA IND clearance for novel mRNA trans-splicing gene therapy, delivering the full-length functional ABCA4 gene to target the genetic root cause of retinal dystrophies associated...
Coave Logo.png
EyeDNA Therapeutics Receives Rare Pediatric Disease Designation from FDA for its Investigational Gene Therapy HORA-PDE6b for Patients with Retinal Dystrophy due to PDE6b Gene Mutations
17. Dezember 2024 06:00 ET | Coave Therapeutics
PDE6b-related Retinitis Pigmentosa is a rare inherited retinal dystrophy affecting up to 3,000 people in the US    Symptoms often start in childhood leading to blindness by midlife with no approved...
aavantgarde_logo.jpg
AAVantgarde announces oral presentation of LUCE-1 clinical study at FLORetina 2024 annual meeting
03. Dezember 2024 02:00 ET | AAVantgarde Bio
AAVantgarde announces oral presentation of LUCE-1 clinical study at FLORetina 2024 annual meeting
aavantgarde_logo.jpg
AAVantgarde Bio Announces FDA Orphan Drug Designation for AAVB-081 for the Treatment of Usher Syndrome Type 1B Retinitis Pigmentosa
02. Dezember 2024 02:00 ET | AAVantgarde Bio
AAVantgarde Bio Announces FDA Orphan Drug Designation for AAVB-081 for the Treatment of Usher Syndrome Type 1B Retinitis Pigmentosa